Clinical trials: Treatment Resistant Major Depression Disorder
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Intravenous Ketamine for Treatment-Resistant Depression
The purpose of this study is to to evaluate the relationships between peak (% change from baseline) central GABA and Glu levels during a 40-min IV ketamine or normal saline infusion utilizing fMRS, and change in peripheral GABA…
- Trial name
- G2K (NCT06668571)
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Depressive Disorder, Depressive Disorder, Major
A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression
The purpose of this study is to evaluate the effectiveness and safety of risperidone to augment SSRI therapy in patients with treatment-resistant depression and to demonstrate the long-term maintenance effect of risperidone as…
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depression
- Trial name
- NCT00044681
- Testing
- risperidone
- Volunteers
- 258 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Major Depression Disorder
Molecular Signatures of TMS Response in Treatment-Resistant Depression
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD).
- Trial name
- PROMET_TMS (NCT07039370)
- Testing
- TMS
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Major Depressive Disorder
Deep rTMS for Treatment-Resistant Late-life Depression
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 who have been unable to tolerate or failed to respond…
- Trial name
- rTMS (NCT01860157)
- Testing
- Brainsway H1-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Centre for Addiction and Mental Health
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Depression, Major Depressive Disorder
Oxytocin and Tibolone Adjuncts in Treatment Resistant Depression - A Pilot Study
The purpose of this study is to determine whether an oxytocin ad-on, or oxytocin and tibolone ad-on can induce a response to antidepressants in patients with treatment resistant depression.
- Trial name
- NCT01239888
- Testing
- Oxytocin, Oxytocin and Tibolone
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- The Alfred
Major Depressive Disorder
Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for eight weeks will be associated with significant increases in frontal lobe phosphocreatine and beta-nucleoside triphosphate (β-NTP)…
- Trial name
- NCT02134808
- Testing
- Creatine
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Major Depressive Disorder
Continuation Ketamine in Major Depression
As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with…
- Trial name
- NCT00548964
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- James Murrough
Depressive Disorder, Major Depressive Disorder
Nitrous Oxide for Major Depressive Disorder
This study aims at investigating the persistence of antidepressant effect of Nitrous Oxide (N2O) for Treatment-Resistant Depression(TRD).
- Conditions
- Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression, Depressive Disorder, Major
- Trial name
- NCT03932825
- Testing
- Nitrous Oxide
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Lingjiang Li
Major Depressive Disorder
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
This is a study that will recruit patients from the neurosurgery clinic and the regular TMS clinic. It's a smaller study designed to collect brain imaging pre-treatment and then use image guided TMS to treat patient with a one…
- Trial name
- NCT05813093
- Testing
- rTMS
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression
Deep Brain Stimulation in Treatment Resistant Depression
Recurrent major depressive disorder affects about 3-5% of the population. It is anticipated that by 2020, depression will be the most common cause of disability worldwide in the 18-55 age group.
- Trial name
- NCT01435148
- Testing
- Deep Brain Stimulation, implanted
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- North Bristol NHS Trust
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Treatment Resistant Depression, Major Depressive Disorder
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures
- Trial name
- NCT04634669
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 20 sites in United States
- Volunteers
- 181 people
- Sponsor
- Axsome Therapeutics, Inc.
Treatment Resistant Depression, Major Depressive Disorder
Dose-Optimized and Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the feasibility, safety, and tolerability of an innovative approach to treating Major Depressive Disorder (MDD), particularly in cases where patients have not responded well to traditional therapies.
- Trial name
- DOS (NCT06730841)
- Testing
- Dose-Optimized and Spaced Transcranial Direct Current Stimulation, Spaced Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Depressive Disorder, Treatment-Resistant
DBS for Treatment Resistant Depression
The purpose of this study is to examine the effects of sub-callosal cingulate (SCC) deep brain stimulation (DBS) in patients with treatment resistant depression (TRD).
- Trial name
- CRIO-DBS (NCT01983904)
- Testing
- deep brain stimulation with short & long pulse width
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company